Editas Medicine, Inc. (EDIT) stock forecast and price target
Price $2.17 · data as of November 13, 2026
12-month price target
Average target$6.10
Upside / downside+181.1%
Analysts10
ConsensusBuy
Low $1.00Average $6.10High $15.00
Gold marker: average target · white marker: today’s price ($2.17)
Analyst ratings
Strong buy 0Buy 9Hold 2Sell 0Strong sell 2
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-0.75 | +58.3% | $33M |
| Next fiscal year ends December 31, 2027 | $-0.73 | +2.9% | $21M |
| Next quarter ends December 31, 2026 | $-0.18 | −202.4% | $7M |
| Quarter after ends December 31, 2026 | $-0.20 | −241.7% | $2M |
Consensus of the analysts covering Editas Medicine, updated daily. In the last 30 days 5 estimates were raised and 1 lowered.
Frequently asked questions
What is the Editas Medicine stock price target?
The average 12-month target from 10 analysts is $6.10, 181.1% above the current price of $2.17 Targets range from $1.00 to $15.00.
Is Editas Medicine a buy according to analysts?
The consensus rating is “Buy” (9 buy, 2 hold, 2 strong sell). Ratings are opinions, not guarantees; this is not investment advice.
How much is Editas Medicine expected to earn?
Analysts expect EPS of $-0.75 for the fiscal year ending December 31, 2026 and $-0.73 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.